Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells

桥粒斑蛋白对肺泡2型细胞肺纤维化的遗传贡献机制研究

基本信息

  • 批准号:
    10736228
  • 负责人:
  • 金额:
    $ 79.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-08-15 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract In recent decades, genome-wide association studies (GWAS) have identified genetic variants associated with a variety of traits and diseases, a critical first step towards understanding the molecular mechanisms that underlie common health conditions. In many cases, however, the functions of GWAS genes, the mechanisms and consequences of their dysfunction, or the relevant cell types in which their dysfunction manifests a clinically significant phenotype remain poorly understood. The GWAS gene DSP encodes a junctional protein found in desmosomes that provide structural integrity to epithelial cells in tissues that experience mechanical stress, such as skin, heart, and lung. A variant associated with DSP expression in lung but not other tissues, rs2076295, has been linked to both pulmonary fibrosis and chronic obstructive pulmonary disease susceptibility in GWAS. In recent years, we and others have developed protocols to differentiate, mature, and model disease in human AT2s derived from iPSCs (iAT2s) and in preparation for this proposal we have adapted this model system to interrogate lung disease-relevant GWAS discoveries. We hypothesize that reductions in DSP mediated through rs2076295 destabilize desmosomes to regulate AT2 phenotypes through modulation of Wnt/Tcf signaling either at homeostasis or in the setting of injury that impairs AT2 differentiation capacity and induces a profibrotic mesenchymal phenotype. To test this hypothesis in this proposal, we will test the mechanisms through which DSP regulates iAT2 maturation through CRISPR-based knockdown or overexpression of DSP or its binding partners. We will identify the contribution of reduced DSP expression on iAT2 transdifferentiation capacity and potential emergence of cells in a transitional state. We will then test the contribution of DSP to AT2 regenerative capacity and associated fibrotic lung injury in vivo using AT2-specific Dsp deletions in mice in combination with bleomycin injury. Finally, we will leverage LTRC data to determine mechanisms through which rs2076295 regulates gene expression and then validate those predictions in patient iAT2s.
项目摘要/摘要 近几十年来,全基因组关联研究(GWAS)已经确定了与 多种特征和疾病,这是了解分子机制的关键第一步 基于共同的健康状况。但是,在许多情况下,GWAS基因的功能,机制 其功能障碍的后果,或它们功能障碍表现出A的相关细胞类型 临床上显着的表型仍然了解不足。 GWAS基因DSP编码连接蛋白 在脱糖体中发现的,可为组织中的上皮细胞提供结构完整性 压力,例如皮肤,心脏和肺部。与肺中DSP表达相关的变体,而不是其他组织, RS2076295已与肺纤维化和慢性阻塞性肺部疾病有关 GWAS的敏感性。近年来,我们和其他人开发了分化,成熟和 源自IPSC(IAT2)的人AT2中的模型疾病,为此提出准备,我们有 调整了该模型系统以询问与肺部疾病相关的GWAS发现。我们假设这一点 通过RS2076295介导的DSP的减少,使脱粒体不稳定,以调节AT2表型通过 调节Wnt/TCF信号在稳态或损害AT2分化的伤害的情况下调节 容量并诱导纤维化间充质表型。为了在该提议中检验这一假设,我们将 测试DSP通过基于CRISPR的敲低或 DSP或其约束伙伴的过表达。我们将确定降低的DSP表达对 IAT2转变能力和在过渡状态下细胞的潜在出现。然后我们将测试 DSP使用AT2特异 小鼠中的DSP缺失与博来霉素损伤结合使用。最后,我们将利用LTRC数据确定 RS2076295调节基因表达的机制,然后验证这些预测 患者IAT2S。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW A WILSON其他文献

ANDREW A WILSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW A WILSON', 18)}}的其他基金

Personalized therapy for AATD-associated liver disease via IPS modeling
通过 IPS 建模对 AATD 相关肝病进行个性化治疗
  • 批准号:
    9518860
  • 财政年份:
    2015
  • 资助金额:
    $ 79.94万
  • 项目类别:
Personalized therapy for AATD-associated liver disease via IPS modeling
通过 IPS 建模对 AATD 相关肝病进行个性化治疗
  • 批准号:
    8888673
  • 财政年份:
    2015
  • 资助金额:
    $ 79.94万
  • 项目类别:
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity
通过调节巨噬细胞 NFKB 和抗蛋白酶活性减轻肺气肿
  • 批准号:
    8294978
  • 财政年份:
    2010
  • 资助金额:
    $ 79.94万
  • 项目类别:
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity
通过调节巨噬细胞 NFKB 和抗蛋白酶活性减轻肺气肿
  • 批准号:
    7953372
  • 财政年份:
    2010
  • 资助金额:
    $ 79.94万
  • 项目类别:
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity
通过调节巨噬细胞 NFKB 和抗蛋白酶活性减轻肺气肿
  • 批准号:
    8117725
  • 财政年份:
    2010
  • 资助金额:
    $ 79.94万
  • 项目类别:
Emphysema attenuation via modulation of macrophage NFKB and antiprotease activity
通过调节巨噬细胞 NFKB 和抗蛋白酶活性减轻肺气肿
  • 批准号:
    8501652
  • 财政年份:
    2010
  • 资助金额:
    $ 79.94万
  • 项目类别:

相似海外基金

Lung developmental defects caused by type I collagen mutations in mouse models of osteogenesis imperfecta
成骨不全小鼠模型中 I 型胶原蛋白突变引起的肺发育缺陷
  • 批准号:
    10735577
  • 财政年份:
    2023
  • 资助金额:
    $ 79.94万
  • 项目类别:
Defining the cellular dynamics that orchestrate alveolar epithelial cell repair behaviors in live mammal
定义协调活体哺乳动物肺泡上皮细胞修复行为的细胞动力学
  • 批准号:
    10556676
  • 财政年份:
    2023
  • 资助金额:
    $ 79.94万
  • 项目类别:
PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study
PNA5:一种新型 Mas 受体激动剂,用于治疗有血管性痴呆和阿尔茨海默氏病相关痴呆风险的患者的认知障碍:FDA 要求的毒理学研究
  • 批准号:
    10705874
  • 财政年份:
    2023
  • 资助金额:
    $ 79.94万
  • 项目类别:
DLL4 in the Developing Lung and Bronchopulmonary Dysplasia (BPD)
DLL4 在发育中的肺和支气管肺发育不良 (BPD) 中的作用
  • 批准号:
    10584811
  • 财政年份:
    2023
  • 资助金额:
    $ 79.94万
  • 项目类别:
Cellular and molecular mechanisms of alveolar repair
肺泡修复的细胞和分子机制
  • 批准号:
    10750085
  • 财政年份:
    2023
  • 资助金额:
    $ 79.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了